Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211 - Gulick, Roy M.; Su, Zhaohui; Flexner, Charles; Hughes, Michael D.; Skolnik, Paul R.; Wilkin, Timothy J.; Gross, Robert; Krambrink, Amy; Coakley, Eoin; Greaves, Wayne L.; Zolopa, Andrew; Reichman, Richard; et al. (The Journal of infectious diseases, 2007)
Keywords: Adult; AIDS; Anti-Retroviral Agents - adverse effects; Anti-Retroviral Agents - therapeutic use; Antiretrovirals; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical trials; Dosage; Double-Blind Method; Drug Therapy, Combination; Female; HIV 1; HIV Infections - drug therapy; HIV Infections - prevention & control; HIV-1 - classification; HIV-1 - drug effects; HIV/AIDS; Human immunodeficiency virus 1; Human immunodeficiency virus 2; Humans; Male; Middle Aged; Piperazines - adverse effects; Piperazines - therapeutic use; Placebos; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Receptors; Ritonavir - therapeutic use; RNA; RNA, Viral - analysis; RNA, Viral - drug effects; Viral Load; Virology; Viruses